NovaBridge Biosciences adopts 2026 Omnibus Share Incentive Plan

NovaBridge Biosciences, a Cayman Islands exempted company, disclosed in a 6-K filing that its board of directors adopted the 2026 Omnibus Share Incentive Plan on July 13, 2026. The plan was adopted by the Board of Directors on July 13, 2026, as its effective date.¹

The new plan replaces five earlier equity programs. It is intended to succeed the predecessor plans, and from the effective date no additional awards may be granted under those predecessor plans, though outstanding awards under them remain subject to their original terms.¹ The predecessor plans are identified as the 2020 Share Incentive Plan, the 2021 Share Incentive Plan, the 2022 Share Incentive Plan, the 2024 Omnibus Incentive Plan, and the 2025 Omnibus Incentive Plan.¹

On share reserves, the filing states the maximum aggregate number of shares authorized for issuance under the plan will not exceed 11,960,000 shares, equivalent to 5,200,000 American Depositary Shares, plus any returning shares that become available over time, plus shares that were reserved but unissued under the predecessor plans immediately before their termination.¹

The plan also includes a mechanism for automatic annual increases to the available share pool. Specifically, the number of shares issuable under the plan is subject to an annual increase on January 1 of each year from 2027 through 2036, set at the lesser of 3% of shares outstanding on the prior December 31 or a smaller number set by the board.¹ The filing does not state that the plan itself terminates in 2036, only that this specific increase schedule runs through that year.

The plan also covers administration, eligibility, vesting terms for options, restricted shares, share units, and provisions governing changes in control, mergers, and dissolution scenarios, according to the filing.